Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker IMUX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Morgan Stanley | 704,244 | 5.2% | SCHEDULE 13G ↗ |
| Nov 2, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | abrdn Inc. | 1.09M | 8.0% | SCHEDULE 13G/A ↗ |
| Nov 2, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Aberdeen Group plc | 1.09M | 8.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Michael Kramarz | 1.51M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Robert Egen Atkinson | 1.51M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Commodore Capital Master LP | 1.51M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Commodore Capital LP | 1.51M | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Daniel Mack | 1.08M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Wilmot B. Harkey | 1.08M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Nantahala Capital Management, LLC | 1.08M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | OrbiMed Capital LLC | 388,540 | 2.8% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | OrbiMed Genesis GP LLC | 756,860 | 5.3% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | OrbiMed Advisors LLC | 756,860 | 5.3% | SCHEDULE 13G ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Guy Levy | 679,200 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Soleus GP, LLC | 679,200 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Soleus Capital Management, L.P. | 679,200 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Soleus Capital Group, LLC | 679,200 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Soleus Capital, LLC | 679,200 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Soleus Capital Master Fund, L.P. | 679,200 | 4.9% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Israel A. Englander | 969,547 | 7.0% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Millennium Group Management LLC | 969,547 | 7.0% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Millennium Management LLC | 969,547 | 7.0% | SCHEDULE 13G/A ↗ |
| Aug 6, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Integrated Core Strategies (US) LLC | 960,816 | 6.9% | SCHEDULE 13G/A ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Janaka Sheehan Maduraperuma | 839,526 | 6.1% | SCHEDULE 13G ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Benjamin Alexander Smith | 839,526 | 6.1% | SCHEDULE 13G ↗ |
| Aug 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Laurion Capital Management LP | 839,526 | 6.1% | SCHEDULE 13G ↗ |
| Jul 16, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | abrdn Inc. | 824,393 | 6.0% | SCHEDULE 13G/A ↗ |
| Jul 16, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Aberdeen Group plc | 824,393 | 6.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Anand Parekh | 6.33M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Alyeska Fund GP, LLC | 6.33M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Alyeska Investment Group, L.P. | 6.33M | 4.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | Zweiman Ari | 474,200 | 3.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | 683 Capital Partners, LP | 474,200 | 3.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | IMUX Immunic, Inc. | 683 Capital Management, LLC | 474,200 | 3.4% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Israel A. Englander | 793,621 | 5.7% | SCHEDULE 13G ↗ |
| May 6, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Millennium Group Management LLC | 793,621 | 5.7% | SCHEDULE 13G ↗ |
| May 6, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Millennium Management LLC | 793,621 | 5.7% | SCHEDULE 13G ↗ |
| May 6, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Integrated Core Strategies (US) LLC | 743,281 | 5.4% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Michael Gregory | 13.96M | 9.9% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Avidity Private Master Fund I LP | 13.96M | 9.9% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Avidity Capital Partners (GP) LLC | 13.96M | 9.9% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Avidity Capital Partners Fund (GP) LP | 13.96M | 9.9% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Avidity Partners Management (GP) LLC | 13.96M | 9.9% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Avidity Partners Management LP | 13.96M | 9.9% | SCHEDULE 13G ↗ |
| Mar 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Deep Track Special Opportunities Fund, LP. | 2.50M | 1.9% | SCHEDULE 13G ↗ |
| Mar 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | David Kroin | 11.45M | 8.7% | SCHEDULE 13G ↗ |
| Mar 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Deep Track Biotechnology Master Fund, Ltd. | 8.95M | 6.8% | SCHEDULE 13G ↗ |
| Mar 4, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Deep Track Capital, LP | 11.45M | 8.7% | SCHEDULE 13G ↗ |
| Feb 24, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Michael Kramarz | 13.35M | 9.9% | SCHEDULE 13G ↗ |
| Feb 24, 2026 | SCHEDULE 13G | IMUX Immunic, Inc. | Robert Egen Atkinson | 13.35M | 9.9% | SCHEDULE 13G ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances